Teva Pharmaceutical Industries
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- -
- Employees
- 37.8K
- Market Cap
- $21.2B
- Introduction
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
FTC Issues New Warnings to Teva and Novartis Over Improper Orange Book Patent Listings
• The Federal Trade Commission has renewed challenges against Novartis, Teva, and other pharmaceutical companies for allegedly improper patent listings in the FDA's Orange Book.
• The disputed listings involve more than 200 patents across 17 brand-name products, primarily for asthma, diabetes, epinephrine autoinjectors, and COPD medications.
• According to the FTC, these improper device patent listings may delay generic competition, artificially inflate drug prices, and restrict patient access to affordable medications.
CellCentric Secures $120 Million Series C Funding to Advance Oral Multiple Myeloma Treatment
• CellCentric has raised $120 million in Series C funding to advance inobrodib, a first-in-class oral p300/CBP inhibitor for multiple myeloma treatment.
• The funding will support a Phase II/III study with potential for accelerated approval, as well as trials combining inobrodib with bi-specific antibodies and in maintenance settings.
• Inobrodib has received FDA Fast Track and orphan drug designation, with promising efficacy and safety data presented at the American Society of Hematology Annual Meeting.
Teva Pharmaceutical Launches $2 Billion Senior Notes Offering to Restructure Debt
• Teva Pharmaceutical Industries Ltd. has announced its intention to issue $2 billion (equivalent) of senior notes through its special purpose finance subsidiaries in both EUR and USD denominations.
• The proceeds will primarily fund tender offers to purchase existing senior notes due between 2026 and 2031, with any remaining funds allocated to repay outstanding debt upon maturity or earlier redemption.
• The notes will be unsecured senior obligations of the issuers and unconditionally guaranteed on a senior basis by Teva, reflecting the company's ongoing debt management strategy.
ADMA Biologics Secures FDA Clearance for Yield Enhancement Process, Poised for Margin Expansion in 2026
• ADMA Biologics has received FDA clearance for a yield enhancement process that is expected to significantly improve production margins for its immunoglobulin products starting in 2026.
• The company plans to strategically allocate its strong cash flow toward debt reduction, commercial initiatives, R&D support, and potential stock repurchases while maintaining financial flexibility.
• Health economic outcome data for ASCENIV is on track for publication later this year, aiming to demonstrate real-world benefits including reduced hospitalizations that justify its premium pricing to payers.
Takeda Spotlights Three Late-Stage Readouts as Potential "Inflection Point" Amid Vyvanse Generic Competition
• Takeda Pharmaceutical is positioning three upcoming late-stage clinical trial readouts as a strategic "inflection point" to offset revenue losses from Vyvanse's generic competition.
• The Japanese pharmaceutical giant is focusing on new product launches and pipeline advancement to maintain growth momentum, with particular emphasis on rare disease and neuroscience therapeutic areas.
• Industry analysts view Takeda's pipeline strategy as critical for the company's long-term financial stability, as it navigates the challenging transition period of losing exclusivity for one of its top-selling medications.
Fremanezumab Shows Dual Efficacy in Treating Both Migraine and Depression in Landmark Trial
• A groundbreaking clinical trial demonstrates that fremanezumab, a CGRP-targeting monoclonal antibody, significantly reduces both migraine frequency and depressive symptoms in patients with comorbid conditions.
• The UNITE study involving 540 patients across 12 countries showed fremanezumab reduced monthly migraine days by 5.1 compared to 2.9 with placebo, with 40% of treated patients achieving at least 50% reduction in migraine days.
• This represents the first placebo-controlled trial to demonstrate significant improvements in both migraine and depression with a single pharmacological intervention, potentially reducing the cumulative burden on patients.
UK Court of Appeal Grants AstraZeneca Interim Injunction Against Glenmark's Generic Dapagliflozin
• The UK Court of Appeal reversed a lower court decision, awarding AstraZeneca an interim injunction against Glenmark's generic dapagliflozin for type II diabetes until the validity hearing judgment.
• The Court ruled that AstraZeneca faced uncertain damages due to inevitable price erosion from multiple generic entrants, while criticizing Glenmark for "jumping the gun" by launching mid-trial.
• Lord Justice Arnold emphasized the importance of orderly dispute resolution, noting that Glenmark's conduct wasted significant court resources for a matter concerning only a one-to-three-month period.
European Launch Sequencing Challenges: Industry Experts Debate Solutions at Reuters Pharma Europe 2025
• Industry experts at Reuters Pharma Europe 2025 debated the challenges of pharmaceutical launch sequencing across 27 EU Member States amid ongoing legislative review, highlighting the need for unified pricing strategies.
• Panelists proposed differential pricing with confidential rebates adapted to GDP per capita as a potential solution to navigate international reference pricing concerns and potential impacts from U.S. policies like Most Favored Nation.
• The Joint Clinical Assessment (JCA) was identified as having significant potential to streamline European market access, though experts emphasized the need for sufficient interaction between companies and decision-makers for successful implementation.
Xolair Shows Superior Efficacy Over Oral Immunotherapy in Landmark Food Allergy Trial
• Phase III OUtMATCH study demonstrates Xolair's superior efficacy with 36% of patients tolerating multiple food allergens compared to 19% in the oral immunotherapy group.
• Xolair treatment showed significantly better safety profile with zero serious adverse events, while oral immunotherapy group experienced 30.5% serious adverse events and higher treatment discontinuation rates.
• Follow-up data reveals promising results for post-Xolair food introduction, with 61-70% success rates for milk, egg, and wheat allergens, though lower rates for nuts.
FDA Removes Ozempic and Wegovy from Shortage List, Sparking Legal Challenge from Compounding Groups
• The FDA has officially removed Novo Nordisk's semaglutide products, Ozempic and Wegovy, from its drug shortage list after being listed since 2022, signaling improved supply availability.
• Compounding groups have filed a lawsuit challenging the FDA's decision, arguing it was made without proper stakeholder consultation and despite ongoing supply challenges acknowledged by Novo Nordisk.
• The legal dispute highlights broader tensions between pharmaceutical manufacturers and compounding facilities over access to semaglutide for treating type 2 diabetes, obesity, and cardiovascular disease.
Biopharma Industry Faces Continued Layoffs in 2025 Amid Strategic Realignments
• Biopharma companies continue to announce layoffs in 2025, driven by strategic realignments, pipeline reprioritizations, and challenging financial conditions.
• Several companies, including Intellia Therapeutics and IGM Biosciences, are cutting a significant portion of their workforce to focus on key programs and extend cash runways.
• These workforce reductions are often accompanied by discontinuation of certain drug development programs and a shift in strategic focus towards core assets.
• The layoffs reflect a broader trend in the industry as companies adapt to evolving market dynamics and prioritize efficiency and long-term sustainability.
AI-Discovered Drug SOM3355 Shows Promise in Treating Huntington's Disease
SOM Biotech's AI-discovered drug, SOM3355, has shown promising results in a phase 2 trial for Huntington's disease, significantly improving symptoms of chorea. The drug, originally developed for high blood pressure, could offer a new treatment option with fewer side effects compared to existing medications.
EMA Accepts GSK's Depemokimab for Review in Asthma and CRSwNP
• The European Medicines Agency (EMA) has accepted GSK's application for depemokimab as an add-on treatment for asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).
• Depemokimab, a monoclonal antibody targeting IL-5, could become the first ultra-long-acting biologic with a six-month dosing schedule if approved.
• Regulatory submissions are supported by positive results from the SWIFT and ANCHOR trials, demonstrating reduced exacerbations and polyp size, respectively.
• Asthma affects over 42 million people in Europe, while CRSwNP impacts up to 4% of the general population, highlighting the need for new treatment options.
Olaparib Shows Sustained Benefit in Early-Stage BRCA-Mutated Breast Cancer
• Olaparib improves long-term survival in women with high-risk, early-stage breast cancer and BRCA1/2 mutations, reducing cancer recurrence risk by 35%.
• After six years, 87.5% of olaparib-treated patients were alive, compared to 83.2% in the placebo group, demonstrating a significant survival advantage.
• The OlympiA trial reinforces the importance of BRCA testing to identify patients who can benefit from personalized olaparib treatment early.
• Olaparib is now recommended by NICE in England and Wales for early-stage, high-risk breast cancer with BRCA1/2 mutations, improving survival chances.
FDA Approves Steqeyma and Yesintek: Expanding Biosimilar Options for Stelara
• The FDA has approved Steqeyma (ustekinumab-stba) and Yesintek (ustekinumab-kfce) as biosimilars to Stelara, offering new options for patients with autoimmune and inflammatory conditions.
• Steqeyma and Yesintek are approved for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, mirroring Stelara's indications.
• These approvals are expected to increase market competition and reduce treatment costs, with launches anticipated in early 2025 following licensing agreements.
FDA Accepts Satsuma and SNBL's NDA Resubmission for STS101 Migraine Treatment
• The FDA has accepted for review Satsuma Pharmaceuticals and SNBL's resubmitted NDA for STS101, a dihydroergotamine nasal powder, for acute migraine treatment.
• The PDUFA date is set for April 30, 2025, offering hope for the nearly 40 million Americans suffering from migraine, especially women in their 20s to 40s.
• STS101 is designed for quick self-administration, leveraging a proprietary nasal delivery device for rapid DHE absorption and sustained plasma concentrations.
• The resubmission addresses FDA's previous concerns related to formulation, with no additional clinical trials requested, marking a significant step toward potential approval.
FDA Approves Ontruzant, Samsung Bioepis and Merck's Biosimilar to Herceptin for Cancer Treatment
• The FDA has granted approval for Ontruzant, a biosimilar version of Roche's Herceptin, developed by Samsung Bioepis and to be marketed by Merck & Co in the United States.
• The biosimilar is approved for multiple indications including HER2-positive breast cancer and metastatic gastric cancer, offering a potentially more affordable treatment option.
• This marks Samsung Bioepis' first FDA-approved oncology biosimilar, joining other competitors like Celltrion/Teva and Mylan in the Herceptin biosimilar market.
BenevolentAI Partners with MRC Technology to Accelerate AI-Driven Drug Discovery
• BenevolentAI and MRC Technology have formed a two-year collaboration to identify and validate novel small molecule and antibody drug candidates using artificial intelligence technology.
• The partnership combines BenevolentAI's deep learning platform with MRCT's screening and drug development capabilities to streamline the discovery of new medicines.
• BenevolentAI's advanced AI system, powered by NVIDIA DGX-1 supercomputer, positions the company as a leading competitor in the growing field of AI-driven pharmaceutical research.
FDA Approves Sandoz's Erelzi as First Enbrel Biosimilar in US
• Sandoz's Erelzi (etanercept-szzs) has received FDA approval as the first biosimilar to Amgen's Enbrel, covering all indications of the reference product for inflammatory diseases.
• The approval marks a significant milestone in the US biosimilars landscape, potentially impacting the $5 billion annual US market for Enbrel.
• The biosimilar approval aligns with healthcare cost reduction goals, with IMS Health projecting potential savings of up to $110 billion by 2020 across the US and five largest EU countries.
© Copyright 2025. All Rights Reserved by MedPath